Short Interest in Prenetics Global Limited (NASDAQ:PRE) Decreases By 24.7%

Prenetics Global Limited (NASDAQ:PRE) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 32,600 shares, a decline of 24.7% from the January 15th total of 43,300 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 14,000 shares, the days-to-cover ratio is currently 2.3 days.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 price target on shares of Prenetics Global in a research report on Thursday, January 16th.

Institutional Investors Weigh In On Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new position in shares of Prenetics Global Limited (NASDAQ:PRE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Prenetics Global Trading Down 1.2 %

NASDAQ:PRE traded down $0.07 on Friday, hitting $5.44. 1,295 shares of the company’s stock traded hands, compared to its average volume of 20,145. Prenetics Global has a 1 year low of $2.85 and a 1 year high of $7.84. The firm has a 50-day moving average price of $5.57 and a 200-day moving average price of $5.03.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, November 27th. The company reported ($0.84) earnings per share (EPS) for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. As a group, equities research analysts forecast that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.